Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood
First-line ART with DTG + 3TC showed similar reductions of HIV-1 persistence parameters and immune markers as DTG + FTC/TAF, supporting DTG/3TC among preferred first-line ART options for PWH.
Authors
- José Moltó (ORCID: https://orcid.org/0000-0003-4564-1963)
- Jacob D. Estes (ORCID: https://orcid.org/0000-0002-9652-6394)
- Albert Caballero‐Solares (ORCID: https://orcid.org/0000-0001-7693-0739)
- Maria Carmen Puertas (ORCID: https://orcid.org/0000-0002-6750-2318)
- Ester Aparicio
- Y. Desyaterik (ORCID: https://orcid.org/0000-0003-0891-5136)
- Àngel Rivero (ORCID: https://orcid.org/0000-0003-2136-0702)
- Kathleen Busman‐Sahay (ORCID: https://orcid.org/0000-0002-8549-0023)
- Lucía Bailón (ORCID: https://orcid.org/0000-0001-7277-9314)
- Maria C. García-Guerrero (ORCID: https://orcid.org/0000-0001-7651-7629)
- Joan Francesc Julián Ibáñez (ORCID: https://orcid.org/0000-0003-2646-2791)
- Àlex Olvera (ORCID: https://orcid.org/0000-0002-9934-5759)
- Beatriz Mothe (ORCID: https://orcid.org/0000-0001-9975-407X)
- Sílvia Marfil (ORCID: https://orcid.org/0000-0003-0139-5000)
- Pep Coll
- Yovaninna Alarcón‐Soto (ORCID: https://orcid.org/0000-0002-9977-8634)
- Sofía Sábato (ORCID: https://orcid.org/0000-0001-8162-8972)
- Stephen Bondoc (ORCID: https://orcid.org/0000-0002-4303-0651)
- Edwards Pradenas (ORCID: https://orcid.org/0000-0001-5162-8920)
- Víctor Urrea (ORCID: https://orcid.org/0000-0002-2577-856X)
- Javier Martínez‐Picado (ORCID: https://orcid.org/0000-0002-4916-2129)
- Igor Moraes-Cardoso (ORCID: https://orcid.org/0000-0003-1011-8849)
- Julià Blanco (ORCID: https://orcid.org/0000-0002-2225-0217)
- Susana Benet (ORCID: https://orcid.org/0000-0002-2219-8826)
- Elias P. Rosen (ORCID: https://orcid.org/0000-0001-5531-7281)
- Christian Brander (ORCID: https://orcid.org/0000-0002-0548-5778)
- Roger Paredes
- Nicole White
- Aroa Nieto
- Cristina Miranda
- Lidia Blai
Institutions
- Oregon National Primate Research Center (US)
- University of North Carolina at Chapel Hill (US)
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Universitat Autònoma de Barcelona (ES)
- Oregon Health & Science University (US)
- Instituto de Salud Carlos III (ES)
- IrsiCaixa (ES)
- Centro de Investigación Biomédica en Red (ES)
- Fundació ACE (ES)
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
- Check Point (Israel) (IL)
- Hospital Universitari Germans Trias i Pujol (ES)
- Vaccine and Gene Therapy Institute
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1093/infdis/jiae530
- Citations
- 11
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.23
Funders
- AstraZeneca
- Gilead Sciences
- ViiV Healthcare
- National Institutes of Health
- University of North Carolina at Chapel Hill
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- National Institute of Allergy and Infectious Diseases